2010 young investigator award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization

Spine

Volumn 35, Issue 9, 2010, Pages 1008-1016

  Schoenecker, Jonathan ^a,b   Mignemi, Nicholas ^a,b   Stutz, Christopher ^a   Liu, Qixu ^b   Edwards, James ^a   Lynch, Conor ^a   Holt, Ginger ^a   Schwartz, Herbert ^a   Mencio, Gregory ^a   Hamm, Heidi ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminocaproic acid; Antifibrinolytics; Aprotinin; Bleeding; Hemostatic agents; Osteoblast; Tissue sealant; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; APROTININ; BONE MORPHOGENETIC PROTEIN 2; PLASMIN; TRANEXAMIC ACID;

ARTICLE; BONE MINERALIZATION; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; STEM CELL;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; AWARDS AND PRIZES; BONE MATRIX; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; OSTEOBLASTS; OSTEOGENESIS; STEM CELLS;

EID: 77951766401     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181d3cffe     Document Type: Article

References (40)

1. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005;93:647-654
2. Keating EM. Current options and approaches for blood management in orthopaedic surgery. Instr Course Lect 1999;48:655-665
3. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;CD001886.
4. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;CD001886.
5. Twite MD, Hammer GB. The use of aprotinin in pediatric cardiac surgery: should we bid 'good riddance' or are we throwing out the baby with the bath water? Paediatr Anaesth 2008;18:809-811
6. Albala DM. Fibrin sealants in clinical practice. Cardiovasc Surg 2003; 11(suppl 1):5-11.
7. Toriseva M, Kahari VM. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009;66:203-224
8. Jenkins G. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008;40:1068-1078
9. Roth D, Piekarek M, Paulsson M, et al. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006;168:670-684
10. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800-1814
11. Tumber A, Papaioannou S, Breckon J, et al. The effects of serine proteinase inhibitors on bone resorption in vitro. J Endocrinol 2003;178:437-447
12. Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res 1995;54-63.
13. Daci E, Udagawa N, Martin TJ, et al. The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 1999;14:946-952
14. Furlan F, Galbiati C, Jorgensen NR, et al. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res 2007;22:1387-1396
15. Plow EF, Herren T, Redlitz A, et al. The cell biology of the plasminogen system. FASEB J 1995;9:939-945
16. Schwab W, Gavlik JM, Beichler T, et al. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin. Histochem Cell Biol 2001;115:317-323
17. Chan JC, Duszczyszyn DA, Castellino FJ, et al. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001;159:1681-1688
18. Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002;22: 399-406.
19. Daci E, Verstuyf A, Moermans K, et al. Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 2000;15:1510-1516
20. Nordstrom SM, Carleton SM, Carson WL, et al. Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization. Bone 2007;41:995-1004.
21. Rundle CH, Wang X, Wergedal JE, et al. Fracture healing in mice deficient in plasminogen activator inhibitor-1. Calcif Tissue Int 2008;83:276-284
22. Sudo H, Kodama HA, Amagai Y, et al. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983;96:191-198
23. Beath SM, Nuttall GA, Fass DN, et al. Plasma aprotinin concentrations during cardiac surgery: full-versus half-dose regimens. Anesth Analg 2000; 91:257-264
24. Oliver WC Jr, Fass DN, Nuttall GA, et al. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2004;127:1670-1677
25. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999;57:233-260
26. Butterworth J, James RL, Lin Y, et al. Pharmacokinetics of epsilonaminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999;90:1624-1635
27. Butterworth J, James RL, Lin YA, et al. Gender does not influence epsilonaminocaproic acid concentrations in adults undergoing cardiopulmonary bypass. Anesth Analg 2001;92:1384-1390
28. Huffman NT, Keightley JA, Chaoying C, et al. Association of specific proteolytic processing of bone sialoprotein and bone acidic glycoprotein-75 with mineralization within biomineralization foci. J Biol Chem 2007;282: 26002-26013
29. Horodyski J, Powell RJ. Effect of aprotinin on smooth muscle cell proliferation, migration, and extracellular matrix synthesis. J Surg Res 1996;66:115-118
30. Brockway WJ, Castellino FJ. The mechanism of inhibition of plasmin activity by e-aminocaproic acid. J Biol Chem 1971;246:4641-4648
31. Aubin JE, Liu F, Malaval L, et al. Osteoblast and chondroblast differentiation. Bone 1995;17:77S-83S.
32. Henry D, Carless P, Fergusson D, et al. The safety of aprotinin and lysinederived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009;180:183-193
33. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-365
34. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-479
35. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331
36. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-783
37. Mouton R, Finch D, Davies I, et al. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008;371:475-482
38. CBS. One Thousand Lives A Month. 60 Minutes. USA: CBS; 2008.
39. FDA. FDA Requests Marketing Suspension of Trasylol. Rockville, MD: FDA; 2007.
40. Gagne JJ, Griesdale DE, Schneeweiss S. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf 2009;18:259-268